Ingen Technologies, Inc. (IGNT), which competes with companies like Siemens AG (SI) and Stryker Corporation (SYK), reported a 17.7% increase in sales for its last two quarters, with an expected larger increase over the next two quarters as its Oxyview product line continues to gain acceptance in the marketplace as the next generation of oxygen therapy devices
YUCAIPA, Calif., March 2, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced that it has increased its marketing and advertising budget now that ISO Certification is near completion, and the Government Services Administration application is near approval.
Ingen will debut the new I-Pulse Oximeter and the new Smart Nasal Cannula with Oxyview technology this coming spring at MedTrade in Las Vegas, the American Thoracic Society in New Orleans, and the Alpha-1 Association's National Education Conference in Orlando.
On May 12, 2010, Ingen will be an exhibitor at the MedTrade Spring convention in Las Vegas, Nevada. The convention connects the HME industry, and allows respiratory leaders to stay ahead of HME industry changes and find the latest tools to help their clients. This is the largest home medical equipment convention in the western U.S. and brings more exhibitors, more ideas, and more products than ever before together under one roof. This is Ingen's opportunity to develop strategic OEM partners and new distributors for the Oxyview product line.
On May 14, 2010, Ingen's consulting partner, MedCo Forum, will introduce the Oxyview product line at the American Thoracic Society in New Orleans, Louisiana. The American Thoracic Society (ATS) is committed to disseminating the latest advances, nationally and internationally, in the fields of lung disease, sleep disorders and critical care medicine. The annual International Conference has become the premier, international forum for physicians and scientists who work in pulmonary, critical care, and sleep medicine. The company will reach 13,000 pulmonologists through the advertising in MedCo Forum's ATS issue that is scheduled to be released on May 1, 2010. MedCo Forum will also host the Oxyview advertising on their website.
On June 11, 2010, Ingen will be an exhibitor at the Alpha-1 Association's National Education Conference in Orlando, Florida. The Alpha-1 Association is a member-based not-for-profit organization dedicated to identifying those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improve the quality of their lives through support, education, advocacy and to encourage participation in research. Alpha-1-Antitrypsin Deficiency (Alpha-1) is a genetic disorder that can cause liver and lung disease in children and adults.
"We look forward to attending these major conventions this spring as we continue to make progress with the introduction of the new I-Pulse Oximeter and the Smart Nasal Cannula with Oxyview technology. We thank all of our shareholders for their continued support and look forward to a very successful future for everyone," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
http://www.medox-oxyview.com/Events.html
http://conference.thoracic.org/
http://www.alpha1.org/education/nateduconf.php
http://www.ipulseoximeter.com/
http://www.smartnasalcannula.com/
About Ingen:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.